• Don Yee, Charles Butts, Anthony Reiman, Anil Joy, Michael Smylie, David Fenton, Quincy Chu, John Hanson, and Wilson Roa.
• Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada. dony@ualberta.ca
• Radiother Oncol. 2012 Feb 1; 102 (2): 234-8.

Background And PurposeTo define the rate of development of symptomatic chest failures in extensive stage small cell lung cancer (ES-SCLC) after undergoing post-chemotherapy chest radiotherapy (RT).Materials And MethodsPatients had ES-SCLC, attained an objective response to chemotherapy and signed study consent. Target accrual was 33 patients. Patients were offered prophylactic cranial irradiation (PCI) as per department policy. PCI (25 Gy/10 fractions) and chest RT (40 Gy/15 fractions) were given simultaneously 4-8 weeks after chemotherapy completion. Thoracic target volume was the post-chemotherapy residual chest disease plus margin. Patients were evaluated for RT toxicities, local control, disease-free and overall survival.ResultsThirty-two patients were evaluable. Twenty-nine patients completed RT without delay. There were 4 complete responses and 28 partial responses to chemotherapy. All study patients received PCI. Maximal acute RT toxicity was grade 2 esophagitis (18 patients). There were no RT-related deaths. Median time to disease progression and overall survival were 4.2 and 8.3 months, respectively (median follow-up=21.8 months). Of 16 chest recurrences, 7 were in the irradiated region and 5 were symptomatic.ConclusionsPost-chemotherapy consolidation chest RT for ES-SCLC patients on this trial was well tolerated and associated with symptomatic chest recurrences in only 5/32 treated patients.Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

33 keywords...

hide…